Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: Neuropharmacology. 2015 Nov 23;102:244–253. doi: 10.1016/j.neuropharm.2015.11.016

Figure 1. VU0467154 increases arousal during wake but does not promote wakefulness.

Figure 1

A-C, percent time awake in 1-h epochs (± SEM) across the 24-h period when dosed 2 h into the light period; open symbols, p<0.05 vs respective vehicle-treated rats. Vertical gray bars in A-C denote the 1-2 hr period post dosing in which spectral power was examined in panels D-F. D-F, changes in relative spectral power in the frontal cortex (% change from baseline, BL) during waking epochs only, during the 1-2 h period following VU0467154 (D), Clozapine (E) and Xanomeline (F) administration. Relative power is summed in 1 Hz bins (0.5-100 Hz) from all 10-sec waking epochs and expressed as a percent change (± SEM) from respective power within the same frequency bin during waking epochs from the 1 h baseline (BL) period prior to dosing. Gray/tan vertical bars represent frequency bands (Δ, delta 0.5-4 Hz; θ theta 4-8 Hz; α alpha, 8-13 Hz; β beta, 13-30 Hz; γ gamma 30-100 Hz). Corresponding colored horizontal dots/lines represent frequencies at each dose that were statistically different from vehicle treated rats (p<0.05, LSD post hoc), n=9-12/group.